Aesica adds HPAPI manufacturing capability
Now offers high potency APIs at commercial scale
Aesica is to upgrade its active pharmaceutical ingredient manufacturing facilities, enabling it to manufacture high potency APIs at commercial scale.
This follows last November’s opening of a new purpose-built US$4.6m high potency manufacturing facility for the manufacture of formulated products in Queenborough, Kent.
The upgrade will ensure Aesica can manufacture SafeBridge Category 3 API and formulated products from pilot to commercial scale from two of its sites in Europe.
The new facilities will enable Aesica to manage high potency API production in quantities from 1kg to 200kg. Further investment in API manufacturing capability in 2013 will equip Aesica to produce batch sizes up to 600kg.
Aesica’s chief executive Dr Robert Hardy predicts that the new high containment formulated product facility and this investment in high potency API production will play a pivotal role in increasing its share of the contract manufacturing market.
‘Opening our new high containment facility for the manufacture of formulated products last year showed that we are extremely committed to this increasingly important marketplace and it was a natural progression to broaden our offering around high potency APIs,’ he said.
